Atmo Biosciences beat 10 other contenders to win the Early Stage Investment Forum (ESIF) at AusBiotech 2019, held at the Melbourne Convention Centre last week.
The ESIF is a key element of the annual AusBiotech conference featuring short pitches from SMEs and research institutions on early stage biotech technology and projects covering areas such as:
- Human therapeutics
- Medical devices
- Digital health
- Enabling technologies
After a selection process with an independent panel, Atmo Biosciences was among 11 projects chosen from across Australia to present six-minute pitches at AusBiotech on Friday 1 November.
Atmo Biosciences CEO Mal Hebblewhite pitched to an expert panel that included representatives from companies including ESIF sponsor BioCurate, as well as Pfizer, Johnson & Johnson Innovation, AbbVie, One Ventures, IP Group, and Brandon Capital Partners.
AusBiotech CEO Lorraine Chiroiu said of the event: “The emerging science presented today is the ‘tip of the iceberg’ of the exciting work being developed in Australia. AusBiotech is pleased to give those projects that do not fit our successful Australia Biotech Invest and Partnering event the opportunity for early and important feedback from a panel of experts.”
The AusBiotech national conference is an annual national conference bringing together more than 1,400 key stakeholders in the Australian and international life sciences sector.